April 17, 2020
Sunovion Pharmaceuticals, a US subsidiary of Sumitomo Dainippon Pharma, said on April 15 that its investigational schizophrenia agent SEP-363856 has hit its primary endpoints in a PII clinical study in the US. In the study, SEP-363856 demonstrated a statistically significant...read more